Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 14 , ISSUE 4 ( October, 2010 ) > List of Articles

RESEARCH ARTICLE

Selection of acute blood purification therapy according to severity score and blood lactic acid value in patients with septic shock

Kunihiro Mashiko, Hisashi Matsumoto, Yoshiaki Hara, Noriyoshi Kutsukata, Hiroyuki Yokota, Yuichiro Sakamoto

Keywords : Acute blood purification therapy, blood lactic acid, septic shock

Citation Information : Mashiko K, Matsumoto H, Hara Y, Kutsukata N, Yokota H, Sakamoto Y. Selection of acute blood purification therapy according to severity score and blood lactic acid value in patients with septic shock. Indian J Crit Care Med 2010; 14 (4):175-179.

DOI: 10.4103/0972-5229.76080

License: CC BY-ND 3.0

Published Online: 01-03-2018

Copyright Statement:  Copyright © 2010; The Author(s).


Abstract

Aim: As an alternative method for acute blood purification therapy, continuous venovenous hemodiafiltration (CVVHDF) has been reported as an effective clinical treatment for critically ill patients, but the optimal column for performing CVVHDF remains controversial. Patients and Methods: We used direct hemoperfusion using a polymyxin B-immobilized fiber column (DHP-PMX) to treat 88 patients with septic shock. To determine the optimal acute blood purification therapy, we subsequently divided the patients into three groups: the first group underwent CVVHDF using a polymethylmethacrylate membrane hemofilter (PMMA) after undergoing DHP-PMX (28 cases), the second group underwent CVVHDF using a polyacrylonitrile membrane hemofilter (PAN) after undergoing DHP-PMX (26 cases), and the third group did not undergo CVVHDF after undergoing DHP-PMX (34 cases). Results: The overall survival rate was 54.5%, and patient outcome was significantly related to the Acute Physiology and Chronic Health Evaluation (APACHE) II score, the sepsis-related organ failure assessment (SOFA) score, and the blood lactic acid value before treatment (all P<0.0001). Only the PMMA-CVVHDF group showed a better outcome (survival rate of 78.6%) compared with the other groups (P = 0.0190). In addition, only the PMMA-CVVHDF group showed a significant improvement in the blood lactic acid level on day 3 (P = 0.0011). Conclusion: Our study suggests that the PMX column might be effective during the early phase of septic shock, before a high level of lactic acid is present. Furthermore, a PMMA column might be the most useful column for performing CVVHDF after DHP-PMX treatment, as suggested by the blood lactic acid value.


PDF Share
  1. Rudiger A, Stotz M, Singer M. Cellular processes in sepsis. Swiss Med Wkly 2008;138:629-34.
  2. Aoki H, Kodama M, Tani T, Hanasawa K. Treatment of Sepsis by Extracorporeal Elimination of Endotoxin Using Polymyxin B-Immobilized Fiber. Am J Surg 1994;167:412-7.
  3. Matsuda K, Hirasawa H, Oda S, Shiga H, Nakanishi K. Current topics on cytokine removal technologies. Ther Apher 2001;5:306-14.
  4. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure: On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Int Care Med 1996;22:707-10.
  5. Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE. APACHE: Acute physiology and chronic health evaluation: A physiological based classification system. Crit Care Med 1981;9:571-9.
  6. Vincent JL. EPIC II: sepsis around the world. Minerva Anestesiol 2008;74:293-6.
  7. Vincent JL, Laterre PF, Cohen J, Burchardi H, Bruining H, Lerma FA, et al. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 2005;23:400-5.
  8. Cruz DN, Bellomo R, Ronco C. Clinical effects of polymyxin B-immobilized fiber column in septic patients. Contrib Nephrol 2007;156:444-51.
  9. Nakada TA, Oda S, Matsuda K, Sadahiro T, Nakamura M, Abe R, et al. Continuous hemodiafiltration with PMMA Hemofilter in the treatment of patients with septic shock. Mol Med 2008;14:257-63.
  10. Peng Y, Yuan Z, Li H. Removal of inflammatory cytokines and endotoxin by veno-venous continuous renal replacement therapy for burned patients with sepsis Burns 2005;31:623-8.
  11. Sakamoto Y, Mashiko K, Obata T, Matsumoto H, Hara Y, Kutsukata N, et al. Effectiveness of continuous hemodiafiltration using a polymethylmethacrylate membrane hemofilter after polymyxin B-immobilized fiber column therapy of septic shock. ASAIO J 2008;54:129-32.
  12. Nakada TA, Oda S, Matsuda K, Sadahiro T, Nakamura M, Abe R, et al. Continuous hemodiafiltration with PMMA Hemofilter in the treatment of patients with septic shock. Mol Med 2008;14:257-63.
  13. Bakker J, Jansen TC. Don′t take vitals, take a lactate. Intensive Care Med 2007;33:1863-5.
  14. Howell MD, Donnino M, Clardy P, Talmor D, Shapiro NI. Occult hypoperfusion and mortality in patients with suspected infection. Intensive Care Med 2007;33:1892-9.
  15. Payen D, Mateo J, Cavaillon JM, Fraisse F, Floriot C, Vicaut E. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med 2009;37:803-10.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.